FOLLOWUS
1. Department of Integrative Oncology, Fudan University Shanghai Cancer Center,Shanghai,China
2. Department of Oncology, Shanghai Medical College, Fudan University,Shanghai,China
3. Department of Integrative Oncology, Zhejiang Province Cancer Hospital,Hangzhou,China
纸质出版日期:2017,
网络出版日期:2017-5-27,
Scan for full text
Song, Lb., Gao, S., Zhang, Aq. et al. Babaodan Capsule (八宝丹胶囊) combined with Qingyi Huaji Formula (清胰化积方) in advanced pancreatic cancer—a feasibility study., Chin. J. Integr. Med. 23, 937–942 (2017). https://doi.org/10.1007/s11655-017-2279-1
Li-bin Song, Song Gao, Ai-qin Zhang, et al. Babaodan Capsule (八宝丹胶囊) combined with Qingyi Huaji Formula (清胰化积方) in advanced pancreatic cancer—a feasibility study[J]. Chinese Journal of Integrative Medicine, 2017,23(12):937-942.
Song, Lb., Gao, S., Zhang, Aq. et al. Babaodan Capsule (八宝丹胶囊) combined with Qingyi Huaji Formula (清胰化积方) in advanced pancreatic cancer—a feasibility study., Chin. J. Integr. Med. 23, 937–942 (2017). https://doi.org/10.1007/s11655-017-2279-1 DOI:
Li-bin Song, Song Gao, Ai-qin Zhang, et al. Babaodan Capsule (八宝丹胶囊) combined with Qingyi Huaji Formula (清胰化积方) in advanced pancreatic cancer—a feasibility study[J]. Chinese Journal of Integrative Medicine, 2017,23(12):937-942. DOI: 10.1007/s11655-017-2279-1.
To observe the clinical effects of Babaodan Capsule (八宝丹
BBD) combined with Qingyi Huaji Formula (清胰化积方
QYHJ) in treating patients with advanced pancreatic cancer. Eighty-one patients with advanced pancreatic cancer (from January 1
2013 to December 31
2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group (40 cases) and QYHJ only group (41 cases)
and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. The cancer-related symptoms of patients such as ascites
jaundice
pain
abdominal distension
anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group (P<0.01). In addition
the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group (65% vs. 33%
respectively
P=0.0023). BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However
it deserves to be further investigated in randomized clinical trials.
To observe the clinical effects of Babaodan Capsule (八宝丹
BBD) combined with Qingyi Huaji Formula (清胰化积方
QYHJ) in treating patients with advanced pancreatic cancer. Eighty-one patients with advanced pancreatic cancer (from January 1
2013 to December 31
2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group (40 cases) and QYHJ only group (41 cases)
and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. The cancer-related symptoms of patients such as ascites
jaundice
pain
abdominal distension
anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group (P<0.01). In addition
the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group (65% vs. 33%
respectively
P=0.0023). BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However
it deserves to be further investigated in randomized clinical trials.
advanced pancreatic cancerBabaodan CapsuleQingyi Huaji FormulaChinese Medicine
advanced pancreatic cancerBabaodan CapsuleQingyi Huaji FormulaChinese Medicine
Long J, Luo GP, Xiao ZW, Liu, ZQ, Long J, Yu XJ. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 2014;346:273–277.
Diaz Beveridge R, Alcolea V, Aparicio J, Segura Á, García J, Corbellas M, Fonfría M, et al. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP Jan 2014;15:19–24.
Ouyang H, Wang P, Meng Z, Yu EX, JIN H, David Z Chang, et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011;40:120.
Liu LM, Wu LC, Lin SY, Yang WH, GUO Y, Xu YF, et al. Therapeutic evaluation on advanced pancreatic cancer Treated by Integrative Chinese and western medicine— Clinical analysis of 56 cases. Chin J Integr Med 2003;9:39–43.
Yehua S, Luming L, Zhen C. Study on Chinese medicine combined with chemotherapy for treatment of 32 cases of advanced pancreatic cancer. J Tradit Chin Med 2006;2:25.
Chen L, Qu C, Chen H, Xu LT, Qi Q, Luo JM, et al. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. PloS One 2014;9:e96177.
Ouyang HQ, Liu LM, Chen Z, Luo JM, Yu EX. Effects of Qingyi Huaji Decoction on serum levels of interleukin-6, interleukin-8 and tumor necrosis factor-alpha in nude mice bearing pancreatic tumors. J Chin Integr Med (Chin) 2010;8:655–661.
Wang P, Chen Z, Meng ZQ, Luo JM, Lin JH, Zhou ZH, et al. Ski acts as therapeutic target of qingyihuaji formula in the treatment of SW1990 pancreatic cancer. Integr Cancer Therap 2010;9:50–58.
Wang P, Liu LM, Chen Z. Effect of Qingyi Huaji Formula for inhibition of pancreatic cancer cell growth through downregulating Ski expression. Chin J Integr Tradit West Med (Chin) 2010;30:942–945.
Yanli X, Feiye Z, Shan X, Liu LM. Anti-tumor effect of the extract from Qingyihuaji Formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1. J Tradit Chin Med (Chin) 2015;35:77–83.
Yin JH, Shi WD, Zhu XY, Chen Z, Liu LM. Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF. Integr Cancer Ther 2012;11:37–47.
Zhang J, Wang P, Ouyang H, Yin JH, Liu AH, Ma CZ, et al. Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. PLoS One 2013;8:e70334.
Sobin LH, Wittekind C. For the international union against cancer: TMN: classification of malignant tumors. New York: NY, Wiley-Liss; 2002:87–89.
Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, et al. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology 2004;66:439–444.
Hong GB, Zhou JX, Sun HB, Li CY, Song LQ. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma. Asian Pacific J Cancer Prevent 2012;13:2669–2673.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin 2015;65:5–29.
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 2014;156:1–14.
Jiang L, Yang KH, Chen Y, Guan QL, Zhao P, Tian GH, et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Sur 2014;101:595–604.
Reese AS, Lu W, Regine WF. Utilization of intensitymodulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Seminars Radiat Oncol 2014;24:132.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Moore JIM, Seay T,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Eng J Med 2013;36:1691–1703.
Xu YL, Gao S, Liu LM, Chen Z, Meng ZQ, Lin JH, et al. Clinical analysis on 20 cases of long term survival patients with advanced pancreatic cancer. China J Tradit Chin Med Pharm (Chin) 2014;29:2679–2681.
Zhou Z, Lin JH,. Proliferation inhibition and apoptosis induction of Ba-Bao-Dan (BBD) in human osteosarcoma U-2OS cells. Chin J Tradit Med Traumatol Orthopedics (Chin) 2006:S2.
Wu H, Li H, Qi X, Pei YX. Effects of Babaodan on myeloidderived suppressor cells proportion of the pripheral blood, spleen and bone marrow in colon carcinoma bearing mice. Chin J Tradit Chin Med 2014;29:568–570.
Feng ZQ, Wu LC, Min-he Shen MH, Shu QJ, Deng YC, Guo-liang Shao GL. Clinical observe report of Babao Pellet Compounded of TACE treating the heat toxic and blood stagnation type patients with primary hepatocellular carcinoma. Chin J Tradit Chin Med 2007;25:2404–2407.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212–2217.
0
浏览量
0
Downloads
3
CSCD
关联资源
相关文章
相关作者
相关机构